Recursion Pharmaceuticals/$RXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Ticker
$RXRX
Sector
Primary listing
Employees
800
Headquarters
Website
RXRX Metrics
BasicAdvanced
$2.1B
-
-$1.80
0.92
-
Price and volume
Market cap
$2.1B
Beta
0.92
52-week high
$12.36
52-week low
$3.79
Average daily volume
17M
Financial strength
Current ratio
3.58
Quick ratio
3.333
Long term debt to equity
7.354
Total debt to equity
9.582
Interest coverage (TTM)
-302.76%
Profitability
EBITDA (TTM)
-586.387
Gross margin (TTM)
-671.05%
Net profit margin (TTM)
-1,004.91%
Operating margin (TTM)
-1,005.81%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-39.08%
Return on equity (TTM)
-86.34%
Valuation
Price to revenue (TTM)
26.902
Price to book
2.27
Price to tangible book (TTM)
5.06
Price to free cash flow (TTM)
-4.384
Free cash flow yield (TTM)
-22.81%
Free cash flow per share (TTM)
-1.102
Growth
Revenue change (TTM)
30.14%
Earnings per share change (TTM)
9.68%
3-year revenue growth (CAGR)
52.89%
3-year earnings per share growth (CAGR)
9.58%
What the Analysts think about RXRX
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
Bulls say / Bears say
After announcing a 20% staff cut, Recursion lowered its projected cash burn to below $450 million for 2025 and under $390 million for 2026, extending its cash runway into Q4 2027 and reducing immediate financing risk.
Second-quarter 2025 GAAP revenue climbed 33% year-on-year to $19.2 million, driven by milestone payments including $7 million from Sanofi, beating expectations and supporting Recursion’s partnership-based business strategy.
The early 2025 acquisition of Exscientia added automated small-molecule chemistry to Recursion OS and is projected to generate annual synergies of over $100 million, strengthening its comprehensive AI-powered drug discovery platform.
Net loss widened to $171.9 million in Q2 2025, up from $97.5 million a year earlier, highlighting significant operating losses that could require more financing if profitability does not accelerate.
Revenue relies entirely on milestone payments and grants, making results volatile and dependent on partners' trial timelines and technical milestones which may be delayed or never achieved.
A 20% workforce reduction to prolong cash reserves signals growing funding challenges in biotech, which could slow R&D progress and point to weaker investor appetite for future non-dilutive capital.
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2025.
RXRX Financial Performance
Revenues and expenses
RXRX Earnings Performance
Company profitability
RXRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.1B as of September 15, 2025.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of September 15, 2025.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.